Tamoxifen and fenretinide in women with metastatic breast cancer

J. Zujewski, L. Pai, L. Wakefield, R. Giusti, F. A. Dorr, C. Flanders, R. Caruso, M. Kaiser, L. Goodman, M. Merino, M. Gossard, M. A. Noone, A. Denicoff, D. Venzon, Kenneth H Cowan, J. A. O'Shaughnessy

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Tamoxifen and fenretinide combination therapy has been shown to be an active treatment regimen in metastatic breast cancer patients. This pilot study sought to determine whether the addition of fenretinide to tamoxifen would be associated with antitumor activity in metastatic breast cancer patients who had been previously treated with tamoxifen or who had hormone receptor negative disease. The effect of this therapy on circulating plasma transforming growth factor-beta (TGF-β) levels and serum lipids was also examined. Patients and Methods: Thirty-one patients were treated with tamoxifen (20 mg po daily), and fenretinide (400 mg po daily with a 3-day drug holiday each month). Plasma TGF-β testing was performed using isoform specific sandwich ELISA. Results: Twenty four of the 31 patients were evaluable for an antitumor response including 14 estrogen receptor (ER) positive patients who had failed prior tamoxifen therapy, seven ER-negative patients, and three hormone therapy naive ER-positive patients. There were no objective antitumor responses; three patients had stable disease for 8, 8, and 24 months. Five patients (16%) discontinued therapy for toxicity (one for grade 3 skin rash and four for abnormal dark adaptation). There was a statistically significant decrease in total cholesterol (median change per patient of -13.5 mg/dl; p = 0.049, a 6.5% decrease), and an increase in HDL levels (median change per patient of +18 mg/dl, p = 0.0001, a 35% increase) with tamoxifen and fenretinide therapy. TGF-β1 plasma levels were normal in 26 of 28 patients, and no changes in these levels post-treatment were demonstrated. Conclusions: Tamoxifen and fenretinide therapy is not an active combination in ER negative metastatic breast cancer or in patients whose disease has progressed on tamoxifen. This combination had a beneficial effect on total serum cholesterol and HDL levels with no associated rise in serum triglyceride levels. The 400 mg dose of fenretinide was associated with symptomatic nyctalopia in one-third of patients making it an unsuitable dose for use in breast cancer prevention studies.

Original languageEnglish (US)
Pages (from-to)277-283
Number of pages7
JournalBreast Cancer Research and Treatment
Volume57
Issue number3
DOIs
StatePublished - Dec 21 1999

Fingerprint

Fenretinide
Tamoxifen
Breast Neoplasms
Estrogen Receptors
Transforming Growth Factor beta
Therapeutics
Serum
Night Blindness
Hormones
Dark Adaptation
Holidays

Keywords

  • Breast cancer
  • Dark adaptation
  • Fenretinide
  • Lipids
  • Tamoxifen
  • Transforming growth factor-β

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Zujewski, J., Pai, L., Wakefield, L., Giusti, R., Dorr, F. A., Flanders, C., ... O'Shaughnessy, J. A. (1999). Tamoxifen and fenretinide in women with metastatic breast cancer. Breast Cancer Research and Treatment, 57(3), 277-283. https://doi.org/10.1023/A:1006216409688

Tamoxifen and fenretinide in women with metastatic breast cancer. / Zujewski, J.; Pai, L.; Wakefield, L.; Giusti, R.; Dorr, F. A.; Flanders, C.; Caruso, R.; Kaiser, M.; Goodman, L.; Merino, M.; Gossard, M.; Noone, M. A.; Denicoff, A.; Venzon, D.; Cowan, Kenneth H; O'Shaughnessy, J. A.

In: Breast Cancer Research and Treatment, Vol. 57, No. 3, 21.12.1999, p. 277-283.

Research output: Contribution to journalArticle

Zujewski, J, Pai, L, Wakefield, L, Giusti, R, Dorr, FA, Flanders, C, Caruso, R, Kaiser, M, Goodman, L, Merino, M, Gossard, M, Noone, MA, Denicoff, A, Venzon, D, Cowan, KH & O'Shaughnessy, JA 1999, 'Tamoxifen and fenretinide in women with metastatic breast cancer', Breast Cancer Research and Treatment, vol. 57, no. 3, pp. 277-283. https://doi.org/10.1023/A:1006216409688
Zujewski J, Pai L, Wakefield L, Giusti R, Dorr FA, Flanders C et al. Tamoxifen and fenretinide in women with metastatic breast cancer. Breast Cancer Research and Treatment. 1999 Dec 21;57(3):277-283. https://doi.org/10.1023/A:1006216409688
Zujewski, J. ; Pai, L. ; Wakefield, L. ; Giusti, R. ; Dorr, F. A. ; Flanders, C. ; Caruso, R. ; Kaiser, M. ; Goodman, L. ; Merino, M. ; Gossard, M. ; Noone, M. A. ; Denicoff, A. ; Venzon, D. ; Cowan, Kenneth H ; O'Shaughnessy, J. A. / Tamoxifen and fenretinide in women with metastatic breast cancer. In: Breast Cancer Research and Treatment. 1999 ; Vol. 57, No. 3. pp. 277-283.
@article{a0347e713c28473a82e63c5fb427c044,
title = "Tamoxifen and fenretinide in women with metastatic breast cancer",
abstract = "Background: Tamoxifen and fenretinide combination therapy has been shown to be an active treatment regimen in metastatic breast cancer patients. This pilot study sought to determine whether the addition of fenretinide to tamoxifen would be associated with antitumor activity in metastatic breast cancer patients who had been previously treated with tamoxifen or who had hormone receptor negative disease. The effect of this therapy on circulating plasma transforming growth factor-beta (TGF-β) levels and serum lipids was also examined. Patients and Methods: Thirty-one patients were treated with tamoxifen (20 mg po daily), and fenretinide (400 mg po daily with a 3-day drug holiday each month). Plasma TGF-β testing was performed using isoform specific sandwich ELISA. Results: Twenty four of the 31 patients were evaluable for an antitumor response including 14 estrogen receptor (ER) positive patients who had failed prior tamoxifen therapy, seven ER-negative patients, and three hormone therapy naive ER-positive patients. There were no objective antitumor responses; three patients had stable disease for 8, 8, and 24 months. Five patients (16{\%}) discontinued therapy for toxicity (one for grade 3 skin rash and four for abnormal dark adaptation). There was a statistically significant decrease in total cholesterol (median change per patient of -13.5 mg/dl; p = 0.049, a 6.5{\%} decrease), and an increase in HDL levels (median change per patient of +18 mg/dl, p = 0.0001, a 35{\%} increase) with tamoxifen and fenretinide therapy. TGF-β1 plasma levels were normal in 26 of 28 patients, and no changes in these levels post-treatment were demonstrated. Conclusions: Tamoxifen and fenretinide therapy is not an active combination in ER negative metastatic breast cancer or in patients whose disease has progressed on tamoxifen. This combination had a beneficial effect on total serum cholesterol and HDL levels with no associated rise in serum triglyceride levels. The 400 mg dose of fenretinide was associated with symptomatic nyctalopia in one-third of patients making it an unsuitable dose for use in breast cancer prevention studies.",
keywords = "Breast cancer, Dark adaptation, Fenretinide, Lipids, Tamoxifen, Transforming growth factor-β",
author = "J. Zujewski and L. Pai and L. Wakefield and R. Giusti and Dorr, {F. A.} and C. Flanders and R. Caruso and M. Kaiser and L. Goodman and M. Merino and M. Gossard and Noone, {M. A.} and A. Denicoff and D. Venzon and Cowan, {Kenneth H} and O'Shaughnessy, {J. A.}",
year = "1999",
month = "12",
day = "21",
doi = "10.1023/A:1006216409688",
language = "English (US)",
volume = "57",
pages = "277--283",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Tamoxifen and fenretinide in women with metastatic breast cancer

AU - Zujewski, J.

AU - Pai, L.

AU - Wakefield, L.

AU - Giusti, R.

AU - Dorr, F. A.

AU - Flanders, C.

AU - Caruso, R.

AU - Kaiser, M.

AU - Goodman, L.

AU - Merino, M.

AU - Gossard, M.

AU - Noone, M. A.

AU - Denicoff, A.

AU - Venzon, D.

AU - Cowan, Kenneth H

AU - O'Shaughnessy, J. A.

PY - 1999/12/21

Y1 - 1999/12/21

N2 - Background: Tamoxifen and fenretinide combination therapy has been shown to be an active treatment regimen in metastatic breast cancer patients. This pilot study sought to determine whether the addition of fenretinide to tamoxifen would be associated with antitumor activity in metastatic breast cancer patients who had been previously treated with tamoxifen or who had hormone receptor negative disease. The effect of this therapy on circulating plasma transforming growth factor-beta (TGF-β) levels and serum lipids was also examined. Patients and Methods: Thirty-one patients were treated with tamoxifen (20 mg po daily), and fenretinide (400 mg po daily with a 3-day drug holiday each month). Plasma TGF-β testing was performed using isoform specific sandwich ELISA. Results: Twenty four of the 31 patients were evaluable for an antitumor response including 14 estrogen receptor (ER) positive patients who had failed prior tamoxifen therapy, seven ER-negative patients, and three hormone therapy naive ER-positive patients. There were no objective antitumor responses; three patients had stable disease for 8, 8, and 24 months. Five patients (16%) discontinued therapy for toxicity (one for grade 3 skin rash and four for abnormal dark adaptation). There was a statistically significant decrease in total cholesterol (median change per patient of -13.5 mg/dl; p = 0.049, a 6.5% decrease), and an increase in HDL levels (median change per patient of +18 mg/dl, p = 0.0001, a 35% increase) with tamoxifen and fenretinide therapy. TGF-β1 plasma levels were normal in 26 of 28 patients, and no changes in these levels post-treatment were demonstrated. Conclusions: Tamoxifen and fenretinide therapy is not an active combination in ER negative metastatic breast cancer or in patients whose disease has progressed on tamoxifen. This combination had a beneficial effect on total serum cholesterol and HDL levels with no associated rise in serum triglyceride levels. The 400 mg dose of fenretinide was associated with symptomatic nyctalopia in one-third of patients making it an unsuitable dose for use in breast cancer prevention studies.

AB - Background: Tamoxifen and fenretinide combination therapy has been shown to be an active treatment regimen in metastatic breast cancer patients. This pilot study sought to determine whether the addition of fenretinide to tamoxifen would be associated with antitumor activity in metastatic breast cancer patients who had been previously treated with tamoxifen or who had hormone receptor negative disease. The effect of this therapy on circulating plasma transforming growth factor-beta (TGF-β) levels and serum lipids was also examined. Patients and Methods: Thirty-one patients were treated with tamoxifen (20 mg po daily), and fenretinide (400 mg po daily with a 3-day drug holiday each month). Plasma TGF-β testing was performed using isoform specific sandwich ELISA. Results: Twenty four of the 31 patients were evaluable for an antitumor response including 14 estrogen receptor (ER) positive patients who had failed prior tamoxifen therapy, seven ER-negative patients, and three hormone therapy naive ER-positive patients. There were no objective antitumor responses; three patients had stable disease for 8, 8, and 24 months. Five patients (16%) discontinued therapy for toxicity (one for grade 3 skin rash and four for abnormal dark adaptation). There was a statistically significant decrease in total cholesterol (median change per patient of -13.5 mg/dl; p = 0.049, a 6.5% decrease), and an increase in HDL levels (median change per patient of +18 mg/dl, p = 0.0001, a 35% increase) with tamoxifen and fenretinide therapy. TGF-β1 plasma levels were normal in 26 of 28 patients, and no changes in these levels post-treatment were demonstrated. Conclusions: Tamoxifen and fenretinide therapy is not an active combination in ER negative metastatic breast cancer or in patients whose disease has progressed on tamoxifen. This combination had a beneficial effect on total serum cholesterol and HDL levels with no associated rise in serum triglyceride levels. The 400 mg dose of fenretinide was associated with symptomatic nyctalopia in one-third of patients making it an unsuitable dose for use in breast cancer prevention studies.

KW - Breast cancer

KW - Dark adaptation

KW - Fenretinide

KW - Lipids

KW - Tamoxifen

KW - Transforming growth factor-β

UR - http://www.scopus.com/inward/record.url?scp=0032761099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032761099&partnerID=8YFLogxK

U2 - 10.1023/A:1006216409688

DO - 10.1023/A:1006216409688

M3 - Article

VL - 57

SP - 277

EP - 283

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -